Therapeutic Plasma Exchange Protocol for 70-kg Lung Transplant Recipient
For a 70-kg lung transplant recipient requiring therapeutic plasma exchange (TPE), perform a 1.5 plasma volume exchange using fresh frozen plasma (FFP) as replacement fluid, which equates to approximately 4,200-4,500 mL total exchange volume.
Volume Calculation
The standard approach for TPE in lung transplantation involves:
- Plasma volume calculation: Approximately 40 mL/kg for adults
- For 70-kg patient: 70 kg × 40 mL/kg = 2,800 mL plasma volume
- Exchange volume: 1.5 × plasma volume = 4,200 mL total exchange
This 1.5 plasma volume exchange represents the evidence-based standard used in sensitized lung transplantation protocols 1.
Replacement Fluid
Use fresh frozen plasma (FFP) exclusively as replacement fluid rather than albumin. While albumin-based exchanges may reduce antibody burden, FFP is strongly preferred in the perioperative lung transplant setting because:
- It maintains coagulation factor levels during a high bleeding-risk procedure
- It reduces (though does not eliminate) coagulopathy risk 2
- Albumin replacement causes severe depletion of coagulation factors, dramatically increasing bleeding complications
Clinical Context and Timing
TPE in lung transplantation is primarily used for:
- Intraoperative desensitization for crossmatch-positive or donor-specific antibody (DSA)-positive recipients 3, 4
- Preoperative preparation when DSAs are identified before transplant 5, 6
- Treatment of antibody-mediated rejection post-transplant 7
Important Caveats
Bleeding risk is real but manageable: Studies demonstrate that intraoperative TPE increases perioperative transfusion requirements (mean 4.2 vs 2.9 packed red blood cell units) and raises odds of large-volume transfusion by 1.9-fold 3. However, this does not translate to increased hemothorax requiring reoperation (5% in both TPE and non-TPE groups) or 30-day mortality (3.5% vs 2.1%) 3.
Coagulopathy occurs even with FFP: Despite using FFP replacement, significant perioperative coagulopathy can still develop, requiring aggressive blood product support 2. Have additional coagulation factors and platelets immediately available.
Temperature management is critical: If TPE is performed for cold agglutinins (rare indication), maintain all fluids and the extracorporeal circuit at ≥37°C 6.
Adjunctive Therapy
When TPE is used for desensitization or DSA treatment, it should be combined with:
- Intravenous immunoglobulin (IVIG): 2 g/kg divided over 2 days, administered after TPE completion 8, 7
- Rituximab: 375 mg/m² (or 1g flat dose), typically given on day 7 after TPE 4
This combination protocol achieves DSA clearance in approximately 65% of patients at hospital discharge 4.
Monitoring During Exchange
- Continuous hemodynamic monitoring
- Ionized calcium levels (citrate anticoagulation causes hypocalcemia)
- Coagulation parameters before and after exchange
- Platelet count
- Core temperature maintenance >36°C
Post-Exchange Assessment
Verify antibody reduction: Obtain post-TPE DSA levels using single antigen bead assay. Successful exchange should render DSAs undetectable or significantly reduce mean fluorescence intensity (MFI) from pre-exchange levels (e.g., from MFI >5000 to undetectable) 1.
The protocol's effectiveness is measured by DSA clearance rather than arbitrary exchange volumes, though 1.5 plasma volumes represents the standard starting point based on published experience 1, 4.